wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35999255-145B92C6-7815-49F5-A19D-530824F3145D
Q35999255-145B92C6-7815-49F5-A19D-530824F3145D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35999255-145B92C6-7815-49F5-A19D-530824F3145D
Emerging targeted therapies for castration-resistant prostate cancer.
P2860
Q35999255-145B92C6-7815-49F5-A19D-530824F3145D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35999255-145B92C6-7815-49F5-A19D-530824F3145D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
683ed4728d77224a8704106f2f14e8b7abcb9752
P2860
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.